Jason M. Broderick | Authors

June 04, 2022

According to new COSMIC-021 data, atezolizumab combined with cabozantinib may be active in patients with urothelial carcinoma.

June 10, 2021

In patients with muscle-invasive bladder cancer treated in the phase 2 HCRN GU16-257 trial, the combination of transurethral resection of the bladder tumor with nivolumab and chemotherapy showed promise.

June 03, 2021

LuPSMA added to standard of care led to a nearly 40% reduction in the risk of death versus standard of care alone in the phase 3 VISION study.

May 19, 2021

Improved outcomes for younger African American patients is associated with increased prostate-specific antigen screening.

February 13, 2021

Localized metastatic lesions were detected with a high correct localization rate (CLR) and positive predictive value (PPV) with the investigational prostate-specific membrane antigen (PSMA)–targeted PET imaging agent 18F-DCFPyL.

May 31, 2020

According to findings from the phase 1b COSMIC-021 trial presented at the 2020 ASCO Virtual Scientific Program, cabozantinib and atezolizumab demonstrated clinically meaningful activity in patients with metastatic castration-resistant prostate cancer, including those with high-risk clinical features.